GlaxoSmithKline Pharmaceuticals announces financial results

GlaxoSmithKline Pharmaceuticals Limited has announced its financial results for the third quarter ended 30th September 2011. While the Company has posted an overall Sales growth of 4 percent compared to the previous quarter, the core pharmaceuticals business grew by 7 percent in this quarter.

Commenting on the performance, Dr Hasit B. Joshipura, Managing Director, said, Vaccine & Speciality franchises continue to register strong double digit growth which includes Dermatology, Oncology, Cardiovascular & Metabolic. The Mass Market businesses and Anti-Infectives were impacted by a relatively lower growth of the market and a high base effect. The ramp up in field force during the course of the year has impacted costs.

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world’s leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information, visit


Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video